Skip to main content
Amanda Wiggins

Amanda Wiggins

Neuroscientist and CEO of The cGP Lab (New Zealand), known for her work on cyclic glycine-proline (cGP), IGF-1 regulation, and brain vascular health.

Feb 4, 2026

16:57
So let's dive a little bit deeper into this diabetes study that you did.
17:03
Yeah, so we enrolled people with type 2 diabetes who'd had diabetes for a minimum of eight years, because the thing we really wanted to look at was peripheral neuropathy, which is a vascular, microvascular complication.
17:19
That's when the nerves, usually in the feet, but not always, it can occur elsewhere, but most commonly in the feet, the nerves start to essentially shrivel up.
17:29
They start shrinking and then they will start retreating from the feet and patients feel phantom sensations, pins and needles, tingling, and eventually as the nerve continues to degenerate, they'll completely lose sensation in the foot and So the problem there is balance.
17:49
One, it's very difficult to balance if you can't feel your foot and damage to the feet.
17:55
So you can't feel if you've stood on something sharp or if you have a diabetic ulcer, which can then become infected.
18:03
And we know that people with type 2 diabetes are somewhere between 8 and 24 times more likely to require an amputation.
19:50
six months, that's an incredible change.

We value your privacy

We use cookies to understand how you use our platform and to improve your experience. Click “Accept All” to consent, or “Decline non-essential” to opt out of non-essential cookies. Read our Privacy Policy.